Preferred term | Continued SDZ ETN (n = 175) n (%) | Switched to SDZ ETN (n = 166) n (%) |
---|---|---|
TEAEs | ||
Nasopharyngitis | 13 (7.4) | 9 (5.4) |
Upper respiratory tract infection | 9 (5.1) | 9 (5.4) |
Urinary tract infection | 7 (4.0) | 2 (1.2) |
Alanine aminotransferase increased | 4 (2.3) | 6 (3.6) |
Injection site reaction | 0 | 6 (3.6) |
Headache | 0 | 4 (2.4) |
Treatment-related TEAEs | ||
Nasopharyngitis | 5 (2.9) | 0 |
Injection site reaction | 0 | 6 (3.6) |